RJA
KYMR icon

Raymond James & Associates’s Kymera Therapeutics KYMR Stock Holding History

Raymond James & Associates’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-26,297
Closed -$366K – 3892
2023
Q3 		$366K Buy
26,297
+1,888
+8% +$38K ﹤0.01% 3070
2023
Q2 		$561K Buy
24,409
+1,478
+6% +$42.4K ﹤0.01% 2863
2023
Q1 		$679K Buy
22,931
+6,150
+37% +$198K ﹤0.01% 2722
2022
Q4 		$419K Buy
16,781
+317
+2% +$8.45K ﹤0.01% 3008
2022
Q3 		$358K Buy
+16,464
New +$434K ﹤0.01% 3070

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Raymond James & Associates's KYMR Position: Q4 2023 in Review

Raymond James & Associates sold out of Kymera Therapeutics (KYMR) in Q4 2023, closing a stake of 26,297 shares — an estimated $366K sold.

Raymond James & Associates first reported a position in KYMR in Q3 2022 and held it in 5 quarters. The position peaked at $679K in Q1 2023. 136 funds tracked by Wall St. Rank hold KYMR as of Q4 2023.

  • Raymond James & Associates reported no remaining Kymera Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 26,297 Kymera Therapeutics shares in Q4 2023, an estimated $366K.
  • Raymond James & Associates first reported a position in Kymera Therapeutics in Q3 2022 and held it in 5 quarters.
  • Raymond James & Associates's Kymera Therapeutics position peaked at $679K in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.